Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
The plan is to advance innovative therapies to drug-resistant cancers
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
